Holocene Advisors’s AbbVie ABBV Stock Holding History

Holocene Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$970K	Buy	+3,855	New	+$829K	﹤0.01%	681
2025 Q3	–	Sell	-3,270	Closed	-$607K	–	734
2025 Q2	$607K	Sell	3,270 -61,830	-95%	-$11.5M	﹤0.01%	689
2025 Q1	$13.6M	Sell	65,100 -1,042,042	-94%	-$203M	0.04%	265
2024 Q4	$197M	Buy	+1,107,142	New	+$204M	0.63%	39
2024 Q3	–	Sell	-1,195,042	Closed	-$205M	–	700
2024 Q2	$205M	Sell	1,195,042 -47,967	-4%	-$7.95M	0.86%	26
2024 Q1	$226M	Sell	1,243,009 -417,484	-25%	-$72M	0.83%	30
2023 Q4	$257M	Buy	+1,660,493	New	+$242M	1%	16
2022 Q1	–	Sell	-1,216,806	Closed	-$165M	–	852
2021 Q4	$165M	Sell	1,216,806 -596,047	-33%	-$70.4M	0.86%	23
2021 Q3	$196M	Buy	1,812,853 +729,682	+67%	+$83.4M	1.06%	15
2021 Q2	$122M	Buy	1,083,171 +195,231	+22%	+$22M	0.69%	35
2021 Q1	$96.1M	Sell	887,940 -354,514	-29%	-$37.9M	0.6%	45
2020 Q4	$133M	Buy	1,242,454 +158,628	+15%	+$15.2M	0.84%	18
2020 Q3	$94.9M	Buy	1,083,826 +466,355	+76%	+$43.9M	0.72%	37
2020 Q2	$60.6M	Buy	+617,471	New	+$54.4M	0.53%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Holocene Advisors's ABBV Position: Q2 2026 in Review

Holocene Advisors opened a new position in AbbVie (ABBV) in Q2 2026: 3,855 shares worth $970K. The stake represents ﹤0.01% of the portfolio and ranks #681 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in ABBV as recently as Q2 2025.

Holocene Advisors first reported a position in ABBV in Q2 2020 and has held it in 14 quarters since. The position peaked at $257M in Q4 2023. 4,230 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Holocene Advisors held 3,855 shares of AbbVie worth $970K as of Q2 2026.
AbbVie was a new Holocene Advisors position in Q2 2026.
AbbVie made up ﹤0.01% of Holocene Advisors's portfolio in Q2 2026, its #681 holding.
Holocene Advisors first reported a position in AbbVie in Q2 2020 and has held it in 14 quarters since.
Holocene Advisors's AbbVie position peaked at $257M in Q4 2023.
4,230 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.